JP2008528621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528621A5 JP2008528621A5 JP2007553304A JP2007553304A JP2008528621A5 JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5 JP 2007553304 A JP2007553304 A JP 2007553304A JP 2007553304 A JP2007553304 A JP 2007553304A JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- des
- weeks
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64749605P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/003116 WO2006081510A2 (en) | 2005-01-27 | 2006-01-27 | Methods for treating renal cell carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011266809A Division JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528621A JP2008528621A (ja) | 2008-07-31 |
| JP2008528621A5 true JP2008528621A5 (cg-RX-API-DMAC10.html) | 2009-01-29 |
Family
ID=36741121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553304A Pending JP2008528621A (ja) | 2005-01-27 | 2006-01-27 | 腎細胞ガンを処置するための方法 |
| JP2011266809A Pending JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011266809A Pending JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Country Status (13)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2370399A4 (en) * | 2008-12-11 | 2013-05-22 | Agency Science Tech & Res | GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EP3443979B2 (en) * | 2011-03-11 | 2026-05-20 | Assistance Publique - Hôpitaux De Paris | IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| US9669071B2 (en) * | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| EP3129493B1 (en) | 2014-04-09 | 2021-07-07 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
| EP3288576A4 (en) * | 2015-04-27 | 2019-01-16 | Susavion Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| KR102777151B1 (ko) * | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| MX2022008770A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Muteinas de la il2. |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| IL301612A (en) * | 2020-10-09 | 2023-05-01 | Synthorx Inc | Immuno oncology therapies with il-2 conjugates |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| CN101028523A (zh) * | 1995-11-30 | 2007-09-05 | 德克萨斯州立大学董事会 | 诊断和治疗肿瘤的方法及组合物 |
| ATE537842T1 (de) * | 2002-07-01 | 2012-01-15 | Wilex Ag | Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms |
-
2006
- 2006-01-27 ES ES06719806T patent/ES2432141T3/es not_active Expired - Lifetime
- 2006-01-27 CA CA002595959A patent/CA2595959A1/en not_active Abandoned
- 2006-01-27 BR BRPI0606774-3A patent/BRPI0606774A2/pt not_active Application Discontinuation
- 2006-01-27 KR KR1020077019556A patent/KR20070102576A/ko not_active Ceased
- 2006-01-27 WO PCT/US2006/003116 patent/WO2006081510A2/en not_active Ceased
- 2006-01-27 JP JP2007553304A patent/JP2008528621A/ja active Pending
- 2006-01-27 US US11/342,243 patent/US20070014765A1/en not_active Abandoned
- 2006-01-27 AU AU2006207987A patent/AU2006207987B2/en not_active Ceased
- 2006-01-27 EP EP06719806.9A patent/EP1846020B1/en not_active Expired - Lifetime
- 2006-01-27 MX MX2007009012A patent/MX2007009012A/es active IP Right Grant
- 2006-01-27 CN CNA2006800067217A patent/CN101132809A/zh active Pending
- 2006-01-27 RU RU2007132125/14A patent/RU2404795C2/ru not_active IP Right Cessation
-
2007
- 2007-07-26 IL IL184865A patent/IL184865A/en active IP Right Grant
-
2009
- 2009-07-28 US US12/460,991 patent/US8012465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 JP JP2011266809A patent/JP2012046552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007132125A (ru) | Способы лечения почечноклеточной карциномы | |
| ES2380107T3 (es) | Combinación de inmunogenoterapia y quimioterapia para el tratamiento del cáncer y enfermedades hiperproliferativas | |
| JP2004524278A5 (cg-RX-API-DMAC10.html) | ||
| IL155730A (en) | Compounds for the treatment of viral hepatitis C | |
| JP2013533858A5 (cg-RX-API-DMAC10.html) | ||
| Hande et al. | Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer | |
| Lissoni et al. | Prognostic Factors of the Clinical Response to Subcutaneous Immunotherapy with lnterleukin-2 Alone in Patients with Metastatic Renal Cell Carcinoma | |
| Pasricha et al. | Treatment of pemphigus with cyclophosphamide | |
| Ellerhorst et al. | Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma | |
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| JP2006514681A5 (cg-RX-API-DMAC10.html) | ||
| Johnson et al. | A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas | |
| Yamao et al. | Phase I–II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer | |
| JP2009539916A5 (cg-RX-API-DMAC10.html) | ||
| JP2007501806A5 (cg-RX-API-DMAC10.html) | ||
| Chaplin et al. | Plegridy for the treatment of RRMS in adults | |
| JP3712914B2 (ja) | 腎細胞ガン処置 | |
| JP2001288110A5 (cg-RX-API-DMAC10.html) | ||
| JP2005529152A5 (cg-RX-API-DMAC10.html) | ||
| Atzpodien et al. | Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-α | |
| HK1045119A1 (zh) | 用於治療癌症的放射性順鉑 | |
| US20080057032A1 (en) | Combination therapy (temozolomide and alpha-ifn) for advanced cancer | |
| Suzuki et al. | Dipyridamole Combined with Tumor Necrosis Factor‐α Enhances Inhibition of Proliferation in Human Tumor Cell Lines | |
| Pavlidis et al. | Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer: A hellenic cooperative oncology group study | |
| ROMINGER | Hydroxyurea and radiation therapy in advanced neoplasms of the head and neck |